Last A$0.17 AUD
Change Today +0.01 / 6.45%
Volume 20.0K
NRT On Other Exchanges
Symbol
Exchange
NASDAQ CM
OTC US
Frankfurt
Stuttgart
As of 2:11 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

novogen ltd (NRT) Snapshot

Open
A$0.16
Previous Close
A$0.16
Day High
A$0.17
Day Low
A$0.16
52 Week High
11/14/13 - A$0.40
52 Week Low
04/16/14 - A$0.15
Market Cap
27.8M
Average Volume 10 Days
296.2K
EPS TTM
A$-0.02
Shares Outstanding
168.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVOGEN LTD (NRT)

Related News

No related news articles were found.

novogen ltd (NRT) Related Businessweek News

No Related Businessweek News Found

novogen ltd (NRT) Details

Novogen Limited operates as a pharmaceutical drug development company worldwide. It focuses on the development of a family of anti-cancer drugs based on super-benzopyran and stealth drug technologies. The company’s lead drug candidate is CS-6, a mitochondrial electron transfer inhibitor for the treatment of temozolomide-resistant glioblastoma multiforme and late-stage chemo-refractory ovarian cancer. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Founded in 1994

novogen ltd (NRT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: A$118.1K
Vice-President of Drug Discovery, Manufacture...
Total Annual Compensation: A$103.5K
Chief Scientific Officer
Total Annual Compensation: A$31.3K
Compensation as of Fiscal Year 2013.

novogen ltd (NRT) Key Developments

Novogen and CanTx Provides Update on its Experimental Drug Trx-1

Novogen Limited and its joint venture company with Yale University, CanTx Inc. announced that its lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells. CanTx is seeking a novel approach to the treatment of abdominal cancers, by developing a product to be administered intra-peritoneally with the ability to seek out tumor cells and to eliminate the full hierarchy of cells within tumors. The final product is envisaged to be Trx-1 in a 'smart' drug delivery system. The first key step in that process was confirmation that Trx-1 alone would be effective. The study reported provides that confirmation. The study was conducted in the laboratories of Gil Mor, M.D., Ph.D, Professor of Obstetrics, Gynecology and Reproductive Science at Yale School of Medicine, and involved an animal model for ovarian cancer considered to be highly representative of the clinical situation. In this model, ovarian cancer stem cells obtained from a patient with refractory ovarian cancer are injected intra-peritoneally, where they grow in a disseminated manner, forming multiple tumors in locations that resemble those observed in patients with ovarian cancer.

Novogen Limited Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 02:30 PM

Novogen Limited Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 02:30 PM. Venue: New York Academy of Sciences, New York, United States. Speakers: Graham Edmund Kelly, Chairman and Chief Executive Officer.

Novogen Limited Announces Board Changes

Novogen Limited announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. Prof. Gunning, prime inventor of the anti-tropomyosin drug technology platform that Novogen acquired in 2013, and Mr. Ross, will complement existing board members, John P O'Connor BEc., MAICD and Steven Coffey CA. The board appointments are effective March 3, 2014, and reflect the expansion of Novogen in the U.S. while maintaining ties to the company's headquarters in Australia. He previously served as Chair of the Division of Research at The Children's Hospital at Westmead, Chair of the Westmead Research Hub Executive and Chair, Board of Bio-Link. Mr. Ross is currently a non-executive director for ASX-listed companies Benitec Biopharma Ltd. and Tissue Therapies Ltd. Prof. Gunning and Mr. Ross replace Mr. Robert Birch (Non-Executive Director and Deputy Chairman) and Dr. Andrew Heaton (Executive Director). Robert Birch originally accepted a Board position on the understanding that his role was to help lay the foundations for a successful company and that he would seek to step down once he was satisfied that those foundations were in place. Likewise, Dr. Andrew Heaton also was appointed originally to help steer the company through its foundation year. Andrew retires in order to focus on his growing role as CEO and President of Novogen North America, and Vice President, Drug Discovery and Manufacture, Novogen Group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRT:AU A$0.17 AUD +0.01

NRT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRT.
View Industry Companies
 

Industry Analysis

NRT

Industry Average

Valuation NRT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.1x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOGEN LTD, please visit www.novogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.